Last reviewed · How we verify

NCT04643704: QUALIM

Quality of Life and Eating Disorders in Children With FPIES, Food Allergy or Celiac Disease

Completed Last updated 28 September 2022
What this trial tests

trial in FPIES in 403 participants. Completed in 22 July 2022.

Timeline
5 January 2021
Primary endpoint
22 July 2022
22 July 2022

Quick facts

Lead sponsorAssistance Publique - Hôpitaux de Paris
StatusCompleted
Study typeOBSERVATIONAL
Enrollment403
Start date5 January 2021
Primary completion22 July 2022
Estimated completion22 July 2022
Sites1 location across France

Conditions studied

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Under 12, any sex, with FPIES or IgE Mediated Food Allergy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Food allergies are associated with a decrease in quality of life. Patients with FPIES often have more food avoidance than necessary. The greater the number of avoided foods, the greater the risk of eating disorders. To date, no study about quality of life or assessment of eating difficulties has been performed in a French-speaking pediatric population with FPIES or celiac disease

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04643704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing